Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: A case-control study

Nichola Johnson, Frank Dudbridge, Nick Orr, Lorna Gibson, Michael E. Jones, Minouk J. Schoemaker, Elizabeth J. Folkerd, Ben P. Haynes, John L. Hopper, Melissa C. Southey, Gillian S. Dite, Carmel Apicella, Marjanka K. Schmidt, Annegien Broeks, Laura J. Van't Veer, Femke Atsma, Kenneth Muir, Artitaya Lophatananon, Peter A. Fasching, Matthias W. BeckmannArif B. Ekici, Stefan P. Renner, Elinor Sawyer, Ian Tomlinson, Michael Kerin, Nicola Miller, Barbara Burwinkel, Frederik Marme, Andreas Schneeweiss, Christof Sohn, Pascal Guénel, Therese Truong, Emilie Cordina, Florence Menegaux, Stig E. Bojesen, Børge G. Nordestgaard, Henrik Flyger, Roger Milne, M. Pilar Zamora, Jose Ignacio Arias Perez, Javier Benitez, Leslie Bernstein, Hoda Anton-Culver, Argyrios Ziogas, Christina Clarke Dur, Hermann Brenner, Heiko Müller, Volker Arndt, Aida Karina Dieffenbach, Stephen J. Chanock, The GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network, kConFab Investigators, Australian Ovarian Cancer Study Group

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Introduction: We have previously shown that a tag single nucleotide polymorphism (rs10235235), which maps to the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary estrone glucuronide levels and a modest reduction in risk of breast cancer in women age ≤50 years. Methods: We further investigated the association of rs10235235 with breast cancer risk in a large case control study of 47,346 cases and 47,570 controls from 52 studies participating in the Breast Cancer Association Consortium. Genotyping of rs10235235 was conducted using a custom Illumina Infinium array. Stratified analyses were conducted to determine whether this association was modified by age at diagnosis, ethnicity, age at menarche or tumor characteristics. Results: We confirmed the association of rs10235235 with breast cancer risk for women of European ancestry but found no evidence that this association differed with age at diagnosis. Heterozygote and homozygote odds ratios (ORs) were OR = 0.98 (95% CI 0.94, 1.01; P = 0.2) and OR = 0.80 (95% CI 0.69, 0.93; P = 0.004), respectively (Ptrend = 0.02). There was no evidence of effect modification by tumor characteristics. rs10235235 was, however, associated with age at menarche in controls (Ptrend = 0.005) but not cases (Ptrend = 0.97). Consequently the association between rs10235235 and breast cancer risk differed according to age at menarche (Phet = 0.02); the rare allele of rs10235235 was associated with a reduction in breast cancer risk for women who had their menarche age ≥15 years (ORhet = 0.84, 95% CI 0.75, 0.94; ORhom = 0.81, 95% CI 0.51, 1.30; Ptrend = 0.002) but not for those who had their menarche age ≤11 years (ORhet = 1.06, 95% CI 0.95, 1.19, ORhom = 1.07, 95% CI 0.67, 1.72; Ptrend = 0.29). Conclusions: To our knowledge rs10235235 is the first single nucleotide polymorphism to be associated with both breast cancer risk and age at menarche consistent with the well-documented association between later age at menarche and a reduction in breast cancer risk. These associations are likely mediated via an effect on circulating hormone levels.

Original languageEnglish (US)
Article numberR51
JournalBreast Cancer Research
Issue number1
StatePublished - 2014
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: A case-control study'. Together they form a unique fingerprint.

Cite this